Autopsy report · NCT01643603
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Cause of deathSlow enrollment
“Study terminated due to slow accrual.”
Life of this trial
- Ran for about 6 years 5 months before it stopped.
- 5 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Myeloid Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Lymphoid Leukemia
- Interventions
- Dasatinib; laboratory biomarker analysis
- Participants
- 5
- Sites
- 1
- Countries
- United States
Trials that died the same way
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
“Study was terminated due to slow accrual.” - CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
“Study terminated due to slow/insufficient accrual.” - Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
“Study was terminated due to slow accrual rate.” - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
“Study terminated due to low accrual.” - Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
“Study has been terminated due to poor accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.